Options Technology’s Festive Donation Funds NI Children’s Hospice over Christmas Holidays

Options Technology, the leading provider of managed services to the global Capital Markets, presented a cheque for £6,000 to Northern Ireland Children’s Hospice to help fund Horizon House and the Community Nursing teams over Christmas Eve and Christmas Day.

The Hospice provides specialist end-of-life care, home care, supported short breaks, and support to children with life-limiting and life-threatening illnesses at their Horizon House facility and through their Community Nursing team. It costs over £1,000 to provide 24 hours of care for one child at Horizon House.

Options, a global company with offices in eight key financial cities worldwide, first opened in Belfast in 2014. From their Belfast headquarters, the team has worked with Northern Ireland Hospice over a number of years, having taken part in their fundraising activities such as their Christmas Toy Appeal.

Options’ President and Chief Executive Officer, Danny Moore, said, “We first became involved with the Children’s Hospice in early 2019, and thoroughly enjoy working with this fantastic group of individuals who deliver such valuable support to families in difficult circumstances across Northern Ireland. Shortly before the pandemic, the team took part in the Hospice’s Christmas Toy Appeal, and while we would have loved to donate toys again this year, this wasn’t possible due to Covid concerns. We are still keen supporters of the Hospice and decided we would cover their running costs for Christmas Eve and Christmas Day.”

Mary McCall, Director of Commercial and Brand Development at Northern Ireland Hospice, added, “We are delighted to receive this donation from Options Technology. Due to ongoing COVID concerns and restrictions, 2021 has been a difficult year in the charity and fundraising sectors. It is only through the generous support from businesses like Options Technology that we can continue to provide care for families across Northern Ireland. We depend on donations like these to continue to provide specialist palliative care to children and infants with life-limiting and life-threatening conditions on a daily basis.”

Today’s news comes as the latest in a series of developments for Options, including the creation of 150 jobs in Belfast following the recent acquisition of ACTIV Financial, expansion into Canada with the Toronto Office Opening, and Thanksgiving donation to the Mourne Mountains Rescue Team.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”